ObjectiveTo explore the clinical efficacy and safety of lithium carbonate combined with ziprasidone in the treatment of patients with bipolar affective disorder in depressive episode. MethodsA total of 66 patients with bipolar affective disorder in depressive episode who were hospitalized in our hospital from April 2019 to May 2020 were selected and randomly divided into study group and control group by the random number method, with 33 cases in each group. Patients in the study group were administrated lithium carbonate combined with ziprasidone, while the patients in the control group were treated with lithium carbonate combined with quetiapine, for a 6-week treatment course. The scores of the Hamilton Depression Rating Scale (HAMD), Hamilton Anxiety Scale (HAMA) and Bech-Rafaelsen Mania Rating Scale (BRMS) were compared between the two groups. The clinical efficacy of the two groups was compared. The Treatment Emergent Symptom Scale (TESS) scores and the incidence of adverse reactions were compared between the two groups. ResultsBefore treatment, there were no statistically significant differences in the scores of HAMD, HAMA and BRMS between the two groups (P＞0.05). At the end of the 6th week of treatment, the scores as above significantly decreased in both groups (P＜0.05), but there was no statistically significant difference in the scores of each scale and the total effective rate between the two groups (P＞0.05). The TESS score and the incidence of adverse reactions in the study group were significantly lower than those in the control group, with statistically significant differences (P＜0.05). ConclusionThe thearpeutic effect of lithium carbonate combined with ziprasidone in the treatment of patients with bipolar affective disorder in depressive episode is comparable to that of lithium carbonate combined with quetiapine; however, the former has fewer adverse reactions and is preferable safety.

无